$ARIA Company News Six

New Post Public Reply Private Reply Replies (0) Message Board

Dec 8, 2014 at 9:13 PM

$ARIA Company News

Six stocks to watch
3:27 p.m. Feb. 26, 2014
- The Trading Deck

6 stocks to watch
3:34 p.m. Feb. 12, 2014
- The Trading Deck

Ariad falls after wild ride upward, while Care.com holds on to its gains

9:02 p.m. Jan. 27, 2014
- Russ Britt

Apple green ahead of earnings; Caterpillar tops gainers
3:42 p.m. Jan. 27, 2014
- Sue Chang

Ariad shares jump nearly 30% on rumors of Big Pharma takeover

1:43 p.m. Jan. 24, 2014
- Russ Britt

5 charts to watch
3:52 p.m. Jan. 15, 2014
- The Trading Deck

Apple closes lower; B. of A. rises on analyst call
4:15 p.m. Jan. 2, 2014
- Wallace Witkowski

Apple gains on China Mobile deal; homebuilders rally
3:33 p.m. Dec. 23, 2013
- Wallace Witkowski

Suspension is lifted for Ariad's leukemia drug
6:33 a.m. Dec. 23, 2013
- MarketWatch.com

J.C. Penney and more of the year's most profitable shorts

3:23 p.m. Dec. 9, 2013
- blogs.marketwatch.com

Hewlett-Packard, a cyclical green light and why silver is in trouble

8:50 a.m. Nov. 26, 2013
- Shawn Langlois

Ariad takes another pounding after leukemia treatment is pulled

12:14 p.m. Oct. 31, 2013
- Russ Britt

H-P has best day in four months on upbeat outlook
3:34 p.m. Oct. 9, 2013
- Sue Chang

Ariad plummets 70% after drug test patients have serious clotting issues

10:38 a.m. Oct. 9, 2013
- Russ Britt

FDA places partial hold on Ariad's Iclusig trials
7:16 a.m. Oct. 9, 2013
- MarketWatch.com

Dan Loeb makes bet on Disney
7:06 p.m. Aug. 14, 2013
- David Benoit

Onyx share surge lifts several boats in biotech harbor, including ETFs

10:33 a.m. July 1, 2013
- Russ Britt

SAC Capital Advisors likes this pharma stock
3:24 p.m. April 18, 2013
- Insider Monkey

Ariad Pharma up 6% to $20.09
10:35 a.m. Dec. 17, 2012
- Steve Gelsi

FDA OKs Iclusig to treat rare types of leukemia
1:06 p.m. Dec. 14, 2012
- MarketWatch.com

ARIAD Reports Long-term Safety, Efficacy Data of Ponatinib from Phase 2 Pace Trial: 83% of CP-CML Patients Achieved Response

6:36 a.m. Today6:36 a.m. Dec. 8, 2014
- benzinga.com

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock

7:06 p.m. Dec. 3, 2014
- TheStreet.com

ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today

10:00 a.m. Dec. 2, 2014
- TheStreet.com

Hottest Healthcare Stocks Now – AVNR BIIB ARIA ACHN

6:15 a.m. Dec. 2, 2014
- InvestorPlace.com

Vargatef cleared in Europe for lung cancer

9:23 a.m. Nov. 28, 2014
- Seeking Alpha

Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape

9:25 a.m. Nov. 25, 2014
- Zacks.com

Iclusig cleared in Australia

10:41 a.m. Nov. 24, 2014
- Seeking Alpha

ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today

10:04 a.m. Nov. 24, 2014
- TheStreet.com

Biggest Movers in Healthcare Stocks Now – ARIA PTCT PTCT CLDX

6:30 a.m. Nov. 24, 2014
- InvestorPlace.com

Biggest Movers in Healthcare Stocks Now – ACAD CYH STJ PODD

6:30 a.m. Nov. 21, 2014
- InvestorPlace.com

Biggest Movers in Healthcare Stocks Now – CLDX ARIA KND MDCO

6:45 a.m. Nov. 20, 2014
- InvestorPlace.com

'Mad Money' Lightning Round: A Group to Avoid

6:00 a.m. Nov. 14, 2014
- TheStreet.com

Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14)

3:40 a.m. Nov. 14, 2014
- Seeking Alpha

10-Q: ARIAD PHARMACEUTICALS INC
4:53 p.m. Nov. 7, 2014
- Edgar Online - (EDG = 10Q, 10K)

Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals

8:58 a.m. Nov. 6, 2014
- benzinga.com

Ariad Pharmaceuticals' (ARIA) CEO Harvey Berger on Q3 2014 Results - Earnings Call Transcript

12:47 p.m. Nov. 5, 2014
- Seeking Alpha

Ariad updates guidance after Q3 results

9:49 a.m. Nov. 5, 2014
- Seeking Alpha

ARIAD Pharmaceuticals (ARIA) Q3 2014 Results - Earnings Call Webcast

8:25 a.m. Nov. 5, 2014
- Seeking Alpha

Notable earnings before Wednesday’s open

5:30 p.m. Nov. 4, 2014
- Seeking Alpha

Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog

5:00 p.m. Nov. 4, 2014
- Zacks.com

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from
Phase 2 Pace Clinical Trial
7:35 a.m. Today7:35 a.m. Dec. 8, 2014
- BusinessWire - BZX

Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison
8:45 a.m. Nov. 25, 2014
- PR Newswire - PRF

ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia
7:35 a.m. Nov. 24, 2014
- BusinessWire - BZX

Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
9:10 a.m. Nov. 14, 2014
- PR Newswire - PRF

ARIAD Announces Iclusig Data Presentations at Annual American Society
of Hematology Meeting
9:44 a.m. Nov. 6, 2014
- BusinessWire - BZX

ARIAD Reports Third Quarter 2014 Financial Results and Development
Progress
7:36 a.m. Nov. 5, 2014
- BusinessWire - BZX

ARIAD to Present at the Stifel 2014 Healthcare Conference
7:35 a.m. Nov. 4, 2014
- BusinessWire - BZX

ARIAD Announces Adoption of Final Opinion for Iclusig by Committee
for Medicinal Products for Human Use in Europe
6:35 a.m. Oct. 24, 2014
- BusinessWire - BZX

Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind
7:55 a.m. Oct. 21, 2014
- PR Newswire - PRF

Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power
7:45 a.m. Oct. 20, 2014
- PR Newswire - PRF

Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics
7:40 a.m. Oct. 15, 2014
- PR Newswire - PRF

ARIAD to Webcast Conference Call on Third Quarter 2014 Financial
Results
6:35 a.m. Oct. 15, 2014
- BusinessWire - BZX

ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance
Risk Assessment Committee of the European Medicines Agency
6:44 a.m. Oct. 10, 2014
- BusinessWire - BZX

ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s
Cell-Signaling Technology
6:35 a.m. Oct. 6, 2014
- BusinessWire - BZX

ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For
ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib
6:35 a.m. Oct. 2, 2014
- BusinessWire - BZX

ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+
Non-Small Cell Lung Cancer
6:35 a.m. Sept. 29, 2014
- BusinessWire - BZX

INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
11:41 a.m. Sept. 16, 2014
- GlobeNewswire

Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
7:55 a.m. Sept. 4, 2014
- PR Newswire - PRF

Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024
12:19 p.m. Aug. 19, 2014
- PR Newswire - PRF

ARIAD Reports Second Quarter 2014 Financial Results and Development
Progress
10:34 p.m. Aug. 6, 2014
- BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

SMPL Faces Legal Drama: What Investors Need to Know

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...